Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Ovid Therapeutics (NASDAQ: OVID) is a New York-based biopharmaceutical company dedicated to the development and commercialization of impactful medicines that transform the lives of patients with rare neurological disorders. The company focuses on targeting the underlying biological pathways of these conditions with precision. Ovid's strategy involves advancing its own pipeline programs and exploring strategic collaborations to bring novel therapies to patients with significant unmet medical needs. Their work is driven by a deep understanding of neuroscience and a commitment to the patient communities they serve.
Serves as the primary corporate center for Ovid Therapeutics, housing executive leadership, clinical development oversight, research management, business development, financial operations, and investor relations.
Located in a modern office building in the vibrant Times Square area of Manhattan, offering excellent connectivity and access to New York City's extensive biotech, financial, and talent resources. Specific internal features are designed for a corporate biopharmaceutical setting.
Ovid Therapeutics likely fosters a dynamic, science-driven, and patient-centric work environment. The culture probably emphasizes collaboration, innovation, urgency in addressing rare diseases, and a strong ethical commitment, typical of biotech firms focused on high unmet medical needs.
The New York City headquarters provides strategic access to global financial markets, a rich pool of scientific and business talent, and a dense network of academic institutions and potential partners, crucial for a publicly-traded biopharmaceutical company.
While Ovid Therapeutics is headquartered in the United States, its operations, particularly clinical trials and research collaborations, may extend globally. The company partners with international research institutions and clinical sites to advance the development of therapies for rare neurological diseases, aiming to serve patients worldwide. Their business development activities also engage with potential partners on a global scale.
1460 Broadway, New York
New York
NY
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Ovid Therapeutics' leadership includes:
Ovid Therapeutics has been backed by several prominent investors over the years, including:
Over the last 12-15 months, Ovid Therapeutics has made significant additions to its executive team, appointing a new Chief Operating Officer and a new Head of Research and Development, reflecting its commitment to advancing its pipeline and strengthening operational leadership. No high-profile executive departures were publicly announced during this specific period.
Discover the tools Ovid Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Ovid Therapeutics commonly uses the email format combining the first initial of an employee's first name with their full last name, followed by '@ovidrx.com'. This is a standard convention in many corporations.
[first_initial][last]@ovidrx.com
Format
jlevin@ovidrx.com
Example
85%
Success rate
Ovid Therapeutics Investor Relations • May 9, 2024
Ovid Therapeutics announced its financial results for the first quarter ended March 31, 2024, and provided updates on its pipeline programs, including progress on its KIF1A associated neurological disorder (KAND) program and soticlestat development....more
Ovid Therapeutics Investor Relations • March 4, 2024
Ovid announced the appointment of Manoj Malhotra, Ed.D., as its new Chief Operating Officer. Dr. Malhotra brings extensive experience in biopharmaceutical operations, strategy, and commercialization to the role....more
Ovid Therapeutics Investor Relations • January 4, 2024
Ovid Therapeutics provided a summary of its significant achievements throughout 2023, including advancements in its research pipeline and corporate milestones, and detailed its strategic priorities for 2024 focused on developing treatments for rare neurological diseases....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Ovid Therapeutics, are just a search away.